Abstract:
The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal 1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2. Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical properties that make it possible to envisage them in diverse solutions for the formulation of medicaments, for example as a pharmaceutically acceptable carrier. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the preparation of a medicament.
Abstract:
The present invention relates to novel octapeptide compounds of general formula (I), R-AA1-cyclo(AA2-Tyr3-D-Trp4-AA5-Val6-Cys7)-Thr8-NH2 (I) As these products have a good affinity for certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) of the somatostatin receptors is (are) involved. The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a medicament.
Abstract:
The invention relates to a process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogues and to pharmaceutical compositions prepared according to the process. In a preferred aspect the process comprises the steps of combining lanreotide acetate and acetic acid, lyophilizing the resulting mixture only once, and hydrating the lyophilizate. Acetic acid may be added to a desired pH during the final step of the process.
Abstract:
The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2. Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical properties that make it possible to envisage them in diverse solutions for the formulation of medicaments, for example as a pharmaceutically acceptable carrier. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the preparation of a medicament.
Abstract:
The invention relates to a long-acting solid formulation for parenteral administration, comprising a) triptorelin acetate and b) one or more excipients comprising a polymer or copolymer of lactic and/or glycolic acid or a mixture of polymers and/or copolymers of lactic acid and/or glycolic acid, said formulation containing 10 to 99% of triptorelin acetate by weight with relation to the total weight of the formulation. Said formulation is obtained by means of a method comprising the fusion of a mixture of triptorelin acetate and the excipient(s) on the fusion/extrusion of the triptorelin acetate with the excipient(s), said formulation being embodied such as to release the triptorelin acetate over a duration of at least one week, once administered parenterally to a patient.
Abstract:
A method comprising the following steps: preparing in a vacuum a dry form (18) of an active principle, as well as a liquid (22), and drawing this liquid into the dry form, by the action of the vacuum to obtain an injectable preparation. The device comprises a gastight syringe (19) to condition under vacuum the dry form, a reservoir (12) containing the liquid (22) and a cap (29) forming a connector between the syringe and the liquid reservoir, the injection needle (25) of the syringe being driven into the septum (24) of the cap (29). The invention enables a preparation which is directly injectable by an automatic rehydration step to be obtained; indeed, after activation, the extemporaneous preparation is automatic since the device elements move by themselves under the action of the liquid which is drawn by suction into the volume under vacuum containing the solid formulation (18).
Abstract:
The invention features an implantable device for the automatic delivery of an active ingredient according to an adjustable delivery profile. The device includes a housing; a reservoir operatively connected to the housing and arranged to store an elongate solid composition including the active ingredient, such as a filament of tape; an actuator arranged within the housing to move the solid composition from the reservoir to a transit assembly, providing a water-tight seal wherein the solid composition exits the housing at the transit assembly; a controller that acts on the actuator to adjust movement of the solid composition out of the housing according to the adjustable delivery profile; and a power source arranged to provide energy to the actuator and the controller. The solid composition can be an elongate, solid composition comprising a drug, and up to 90% of a carrier, wherein the composition has a cross-section of less than 0.5 mm, and wherein the drug and the carrier are selected and compounded in a proportion such that the drug is immediately released from the carrier upon contact with a liquid.
Abstract:
The invention features a method of administering a peptide to a patient and delivering the peptide continuously over an extended period of time of at least three days by obtaining a solid pharmaceutical composition including a soluble, gelable salt of the peptide and up to 30 percent, by weight, of a pharmaceutically acceptable, soluble, monomeric carrier, and parenterally administering the solid composition to the patient in one injection, wherein the solid composition automatically forms a gel after interaction with the patient's bodily fluids and releases the peptide continuously within the patient over an extended period of at least three days.
Abstract:
An osmotic pump comprises a housing (2) within which is a delivery chamber (5) separated from an osmotic salt chamber (7) by impermeable moveable pressure responsive means such as a piston (6) or a flexible membrane. The osmotic salt chamber (7) is separated from a source of osmotic fluid, e.g. an osmotic fluid chamber (12), by a semipermeable membrane (96,36), optionally mounted in a piston (9,23). A fluid barrier isolates the osmotic salt chamber (7) from the source of osmotic fluid for storage of the pump, and may be inactivated when the pump is to be used. The fluid barrier may be a foil sheet (10), inactivatable by rupture, or a piston and a fluid bypass arrangement (21,23). Activation of the osmotic pump may be effected in some embodiments by loading the discharge chamber (5) with the agent to be delivered and in other embodiments by movement of a plunger (16), under manual control or, if the plunger is pre-biassed, by release of a locking means (18) which holds it in position.
Abstract:
The invention relates to a method for preparing linear polymers having an amide end or having a star architecture comprising an amide core, by means of a ring opening using lactide and glycolide monomers or a lactide monomer ring in the presence of a catalyst, wherein the method includes the steps of: (i) reacting the excess monomer(s) with an initiator in a solvent, said initiator being selected from among an amine and an amino alcohol, given that the initiator has at least one primary or secondary amine function; (ii) adding a catalyst, said catalyst being a non-nucleophilic base and including at least one neutral sp2 nitrogen atom; and (iii) neutralizing the reaction mixture. Said novel method is particularly advantageous in that it can be easily monitored and enables better modulation of the polymers, and thus of the properties thereof, than the methods of the prior art. The invention also relates to novel polymers that are obtainable by means of said method.